A major role for CD4(+) T cells in driving cytokine release syndrome during CAR T cell therapy

Anti-CD19 chimeric antigen receptor (CAR) T cell therapy represents a breakthrough for the treatment of B cell malignancies. Yet, it can lead to severe adverse events, including cytokine release syndrome (CRS), which may require urgent clinical management. Whether interpatient variability in CAR T c...

Descripción completa

Detalles Bibliográficos
Autores principales: Boulch, Morgane, Cazaux, Marine, Cuffel, Alexis, Ruggiu, Mathilde, Allain, Vincent, Corre, Béatrice, Loe-Mie, Yann, Hosten, Benoit, Cisternino, Salvatore, Auvity, Sylvain, Thieblemont, Catherine, Caillat-Zucman, Sophie, Bousso, Philippe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10518592/
https://www.ncbi.nlm.nih.gov/pubmed/37595589
http://dx.doi.org/10.1016/j.xcrm.2023.101161

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10518592/
https://www.ncbi.nlm.nih.gov/pubmed/37595589
http://dx.doi.org/10.1016/j.xcrm.2023.101161

Ejemplares similares